A team of pediatric oncologists led by PD Dr. Anton G. Henssen has set out to further improve our understanding of the mechanisms involved in cancer development and disease progression. PD Dr. Henssen, a researcher at the Experimental and Clinical Research Center (ECRC) - a facility jointly operated by Charité - Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine (MDC) - suspects genome-level adaptations as the driving force behind these mechanisms.
The aim of the CancerCirculome project is to improve our understanding of ecDNA - ring-shaped sections of DNA which are found inside our cells but do not form part of our normal genetic information. The objective is to use cancer cell-specific characteristics of these DNA sections to inform treatment, diagnosis and clinical prognosis. The European Research Council (ERC) has allocated a total of approx. €1.5 million for the establishment of this new research group.
The research community is increasingly turning its attention to the role of extrachromosomal DNA in cancer development. According to the latest research, cancer cells appear to have the ability to produce small, ring-shaped sections of extrachromosomal DNA known as ecDNA, which they can then reintegrate into existing chromosomal DNA. If the original order of DNA segments is disrupted, this can lead to the dysregulation of cell growth and cancer.
We have already shown that this phenomenon occurs more frequently than previously thought in primary neuroblastoma, a type of cancer found primarily in children. This observation suggests that the circularization of DNA is an important driver behind the remodeling of cancer cell DNA".
PD Dr. Henssen, Physician at Charité's Department of Pediatrics, Division of Oncology and Hematology
The launch of the CancerCirculome project will see the pediatric oncologist and Emmy Noether Independent Junior Research Group leader work alongside his research team to unravel the principles governing DNA modifications in pediatric cancers. Over the next five years, the researchers will focus on the mechanisms and effects of DNA circularization and the reintegration of DNA fragments into chromosomes. "The details of how ecDNA is made and how it replicates remain unknown. To get closer to identifying the origin of these tiny ring-shaped fragments, we will reconstruct the exact DNA sequences they contain," explains PD Dr. Henssen. He adds: "To do this we will identify the molecular factors responsible for the generation and replication of ecDNA at the single-cell level."
The team hope to discover previously unknown mechanisms which cause cells to lose control over cell growth and proliferation. "These mechanisms could be used as new diagnostic and treatment targets - not just in pediatric cancers, but as a fundamental principle governing all cancers," says PD Dr. Henssen, who is also a BIH Charité Clinician Scientist and a researcher at the German Cancer Consortium (DKTK). Using single-cell CRISPR-based methods (which enable researchers to alter and disrupt ecDNA in a targeted manner), the researchers will attempt to demonstrate the biological effects of DNA circularization and reintegration.
The researchers plan to target and manipulate the genetic information contained in ecDNA fragments inside human cells in order to evaluate their effects on cancer cell fitness and function. The researchers also plan to study the behavior, presence and genomic integration of these fragments at the single-cell level during cancer treatment. The aim is to uncover the oncogenic role of ecDNA and determine the mechanisms responsible for the reintegration of ecDNA into chromosomes.
The researchers hope to translate this knowledge into clinical benefits for patients. "We hope to use our understanding of the underlying principles to define novel diagnostic and predictive markers which could then be used for the personalized diagnosis, risk assessment and treatment of cancers," concludes PD Dr. Henssen. The researchers' long-term aim is to contribute to and inform our understanding of different cancers, and to support clinical trials involving personalized treatments for children with difficult-to-treat cancers.